Saira Butt, MD

Roon for Doctors A new way for doctors to learn from each other—fast. Roon for Doctors offers perspectives from medical experts on relevant questions in medicine.

www.roon.com/doctors/invi... new social media platform #meded #idmeded

#CROI2026 #idsky #DOLPHIN-Moms: Pharmacokinetics & HIV Suppression With Once-Daily #Dolutegravir & #3HP in #Pregnancy presented by Jyoti Mathad: median troughs 158 ng/dl. >90% women maintained viral suppression while on once daily dolutegravir+3HP w/excellent safety

#CROI2025 #idsky Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis presented by Sean Wasserman:
-DTG clearance markedly increased by RPT 1200mg co-administration
-DTG bid dosing with RPT-based TB tx:
therapeutic, safe, achieved Viral suppression

#CROI2026 #idsky One-Month 1HP (daily rifapentin/INH) Versus 3-Month 3HP (wkly) Rifapentine-Based Tuberculosis Preventive Therapy (TPT) in #PLW presented by Anchalee Avihingsanon:
-IHP non-inferior to 3HP for TPT,
-safe/well tolerated,
-No DTG dose adjustment required

#croi2026 #idsky Hepatitis flare occur in some participants after stopping tx (liver function should be monitored for 6mo post stopping tx). 2 participants coinfected w/HIV/HBV/HDV achieved combined virologic/biochemical response. 2/

#CROI2026 #idsky Efficacy & Safety of Bulevirtide (BLV) 2 or 10 mg in Chronic Hepatitis Delta (CHD) Including Patients With HIV/HBV: MYR301 Final Results presented by David Wyles. Long term BLV monotherapy for CHD for upto144wks was safe/effective (higher rates of undetectable virus w/10mg dose. 1/

#croi2026 #idsky 2/
-HBVr/i occured despite pre-switch HBsAb+ which may reflect waned HBV immunity
-Strongest predictors of HBVr/i: Low CD4 at time of switch, Black & Asian race
-Transaminase elevation was uncommon in this cohort

#croi2026 Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy presented by
Grace Haser (UCSF): 1/ #idsky
-Complete HBV serologies were not available prior to TXF sparing ART switch in 29% of cohort
-HBV reactivation (r/i) rare (0.4%)

#IDsky sharing one of the Stanford's ID fellow's meded site infectiousdiseasehub.com #idmeded #meded

#CROI2026 #idsky #HIVsky Poster: An Ultra-Long-Acting #Buprenorphine Prodrug (AM-510) for Opioid Use Disorder: by Ashrafi Sultana.
A single SC dose of AM 510 sustains plasma concentrations of BUP above target Ctrough of clinically efficacious oral SUBOXONE for over 5 months.

#CROI2026 #idsky Metabolic Syndrome & Cognitive Impairment Among Men With & Without HIV: presented by
Sara Hockney (Northwestern U): Age >65 dominant predictor; stronger effect #PWH. Metabolic syndrome not independently associated with cognition. Age>65+Metabolic syndrome highest overall impairment

#CROI2026 #idsky #MASH & Progression of Cognitive Decline in Older #PWH: A Prospective Study presented by Katekarn Porkaew (Chulalongkorn University, Bangkok, Thailand): MASH was independently associated with accelerated cognitive decline in older PWH followed over 6 years

Protection benchmarks for LA PrEP with NRTI may needto be adjusted to account for drug-resistant viruses while maintianing safety. 2/ #croi2026 #idsky

#croi2026 #idsky Implants Releasing NRTTI MK-8591 Fail to Protect Macaques Against SHIV Containing the M184V Mutation, presented by Charles Dobard. Findings highlight potential vulnerability of single-agent PrEP with agents that share resistance pathways with ART commonly used for treatment. 1/

Gut bacteria-specific cells are enriched in intact HIV genomes. These cells represent a chronically antigen-stimulated niche that sustains long-term HIV persistence during ART 2/ #croi2026

#croi2026 #idsky presented by Armando Espinosa Ortiz/Univ of Montreal: Bacteria specific CD4 T cells are depleted during untreated HIV & only partially restored with ART. There is phenotypic drift of these cells towards cytotoxic phenotype, which has been linked to HIV persistence. 1/

#croi2026 #hivsky #idsky 513 - Phase III Efficacy and Safety of Switch From B/F/TAF to Single-Tablet BIC/LEN in #ARTISTRY-2
presented by Eric Meissner: BIC/LEN maintained high levels of virologic suppression at week48 & non-inferior to B/F/TAF

#croi2026 #idweek Effect of DTG/3TC vs BIC/FTC/TAF on Steatotic Liver Disease (SLD): 96-Week Analysis of PASO-DOBLE Trial: In virologically suppressedPLWH switching to BIC/FTC/TAF associated with higher frequency of SLD compared to DTG/3TC after 96 weeks of therapy #hivsky #PASODOBLE

#croi2026 #idsky #hivsky Plenary by Ilesh Jani: Uneven progress: decline in 40% of new HIV infections globally (2010-2024) with uneven progress between regions. Appox 21 million lives saved by 2022 (54% decline in deaths). Unmet needs ART: East/south Africa 36%. Not on path to 2030 target

#croi2026 oral abstract session #idsky #hivsky #pitavastatin has benefit beyong lipid lowering: reduces incident HTN (2 fold higher major adverse cardiac risk/ #MACE) in #PLWH

#CROI2026 #idsky #hivsky #lenacapavir moderate cytochrome P450 (CYP) 3A4 inhibitor: some meds cant be co-administer, many drug interactions: needs close monitoring. No interaction with hormone therapy. Look it up clinicalinfo.hiv.gov/en/guideline...

When and How to Use Subcutaneous Antibiotics

✅ Just Accepted
🔗 https://bit.ly/3NB1jH5

Short-Course Tuberculosis Preventive Therapy in a High Migration Setting: Early Experience With 1HP in Cook County, Illinois

✅ Just Accepted
🔗 https://bit.ly/4r7HlCk

Grateful to have the opportunity to share this little piece of my heart. Love is always the answer.

academic.oup.com/cid/advance-...

#idsky #idweek2025 session 'Beyond 101: Pondering Perplexing Prescribing Issues': Oral Beta-Lactams for Severe Gram-Positive Infections: Ready for Prime Time? by
Dr. Nguyen (U Chicago Med): lots of pearls in this talk. Wanted to share: bioavailability of oral b-lactams @cynth-id.bsky.social

29 IE pts (72%♂, mean 67y), 76% met POET criteria; oral abx after ~15d IV, 26d oral; 3 adverse outcomes (2 embolic, 1 death); linezolid common but caused changes in 6 pts.⚕️

#idsky

How the Z-Pak Took Over Outpatient Medicine, Part 2: The Reckoning Share Tweet Pin Mail SMS Part 1 of this azithromycin series explained how the drug became ubiquitous. In Part 2, we’ll explore why many ...

Azithromycin: once a pharmacologic breakthrough, now a textbook case of overuse.
Part 2 explores resistance, muddled diagnoses, and the cases where it's still arguably the drug of choice. #IDSky #Medsky

blogs.nejm.org/hiv-id-obser...

How Should We Interpret the Changes to the Childhood Vaccine Schedule? | Contagion Live Former FDA Chief Scientist, Jesse L. Goodman, MD, MPH, provides insights on the potential consequences of these new recommendations.

Former FDA Chief Scientist, Jesse L. Goodman, MD, MPH, provides insights on the potential consequences of these new recommendations. #IDsky #Medsky

Just published new #breakpoints by #EUCAST.
#Bad news: values for #TMP_SMX have been significantly #lowered for key #pathogens.
Bad news under an #antimicrobial_stewardhisp perspective since the combination is a cornerstone of #Oral_is_the_new_IV.

@escmid.bsky.social #IDSky.

And there it is: FDA has approved zoliflodacin for gonorrhea as well.
That makes two new antibiotics to treat this STI and it means a fascinating debate now about how to use these drugs in a way that will delay resistance as much as possible…
🧪 #IDsky